Brendan J Classon, PhD

Brendan J Classon, PhD

Company: Parvus Therapeutics

Job title: Executive VP, Research & Development


Leveraging A Natural Differentiation Pathway of T Regulatory-1 (TR1) Cell to Fuel a Nanomedicine Approach to Treat Autoimmune Disease 3:00 pm

Showing how T-follicular Helper (TFH) cells can serve as in vivo precursors of TR1 cells in humans and in mice Describing complete differentiation of TR1 effector function, requiring the transcription factor Blimp-1 (Prdm1) Presenting Navacims, a pMHC-II nanomedicine platform to induce TFH expansion and differentiation to immunomodulatory TR1 cellsRead more

day: Day one Track 2 PM

Expert Panel: Optimizing Routes of Administration & Delivery Mechanisms to Induce Timely Treg Specific Activation With 11:30 am

Read more

day: Day two track 2 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.